Alkermes Plc (ALKS):企業の財務・戦略的SWOT分析

◆英語タイトル:Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15778
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥16,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥32,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥48,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Alkermes Plc (ALKS) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development and commercialization of drugs for the treatment of central nervous system (CNS) diseases. The company’s proprietary products include Aristada, an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, a once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It also grants license under its proprietary technologies to enable third parties to develop, commercialize and manufacture products. Alkermes sells its products primarily to wholesalers, specialty distributors and specialty pharmacies. The company also has a clinical pipeline of products that address CNS disorders such as multiple sclerosis, schizophrenia, depression and addiction. Alkermes is headquartered in Dublin, Ireland.

Alkermes Plc Key Recent Developments

Mar 22,2019 Alkermes Statement on National Academies of Sciences, Engineering, and Medicine Report on Medications for Opioid Use Disorder
Feb 14,2019 Alkermes Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019
Jan 16,2019 Alkermes announces recipients of 1st annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Alkermes Plc – Key Facts
Alkermes Plc – Key Employees
Alkermes Plc – Key Employee Biographies
Alkermes Plc – Major Products and Services
Alkermes Plc – History
Alkermes Plc – Company Statement
Alkermes Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Alkermes Plc – Business Description
Geographical Segment: Ireland
Performance
Geographical Segment: Rest of world
Performance
Geographical Segment: US
Performance
R&D Overview
Alkermes Plc – Corporate Strategy
Alkermes Plc – SWOT Analysis
SWOT Analysis – Overview
Alkermes Plc – Strengths
Alkermes Plc – Weaknesses
Alkermes Plc – Opportunities
Alkermes Plc – Threats
Alkermes Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Alkermes Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 22, 2019: Alkermes Statement on National Academies of Sciences, Engineering, and Medicine Report on Medications for Opioid Use Disorder
Feb 14, 2019: Alkermes Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019
Jan 16, 2019: Alkermes announces recipients of 1st annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program
Nov 30, 2018: Statement by Richard Pops, Chairman and CEO of Alkermes on the annual CDC report on Drug Overdose deaths and suicide mortality in the United States
Nov 29, 2018: Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia
Oct 29, 2018: Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder in Molecular Psychiatry
Oct 26, 2018: Alkermes announces recipients of 3rd Annual ALKERMES INSPIRATION GRANTS
Oct 26, 2018: Alkermes announces recipients of 3rd Annual ALKERMES INSPIRATION GRANTS
Oct 23, 2018: Alkermes announces third quarter 2018 financial results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Alkermes Plc, Key Facts
Alkermes Plc, Key Employees
Alkermes Plc, Key Employee Biographies
Alkermes Plc, Major Products and Services
Alkermes Plc, History
Alkermes Plc, Other Locations
Alkermes Plc, Subsidiaries
Alkermes Plc, Key Competitors
Alkermes Plc, Ratios based on current share price
Alkermes Plc, Annual Ratios
Alkermes Plc, Annual Ratios (Cont...1)
Alkermes Plc, Annual Ratios (Cont...2)
Alkermes Plc, Interim Ratios
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Alkermes Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Alkermes Plc, Performance Chart (2014 - 2018)
Alkermes Plc, Ratio Charts
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Alkermes Plc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Alkermes Plc (ALKS):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • GKN plc:企業の戦略・SWOT・財務情報
    GKN plc - Strategy, SWOT and Corporate Finance Report Summary GKN plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Delphi Genetics SA-製薬・医療分野:企業M&A・提携分析
    Summary Delphi Genetics SA (Delphi Genetics) is a genetic engineering and bioproductions company that develops products and technologies for gene cloning and protein expression in bacteria. The company offers services which include gene synthesis, DNA cloning and mutagenesis Plasmid production, prot …
  • Eckoh PLC (ECK):企業の財務・戦略的SWOT分析
    Summary Eckoh PLC (Eckoh) is a technology service provider that offers secure payment products and customer service solutions. The company provides agent assisted payments, IVR payments, mobile and web payments and GPDR. Its agent assisted payments include DTMF Masking, audio tokenization, alternati …
  • Labrador Iron Mines Holdings Limited:企業の戦略・SWOT・財務分析
    Labrador Iron Mines Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Labrador Iron Mines Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Boehringer Ingelheim GmbH:企業のM&A・事業提携・投資動向
    Boehringer Ingelheim GmbH - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Boehringer Ingelheim GmbH Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • BESIX Group SA:企業の戦略的SWOT分析
    BESIX Group SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Whirlpool Of India Limited:企業の戦略・SWOT・財務情報
    Whirlpool Of India Limited - Strategy, SWOT and Corporate Finance Report Summary Whirlpool Of India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • China Gezhouba Group Co Ltd (600068):企業の財務・戦略的SWOT分析
    China Gezhouba Group Co Ltd (600068) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • H.I.G. Capital LLC:企業の戦略的SWOT分析
    H.I.G. Capital LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • VisionQuest Biomedical LLC:企業の製品パイプライン分析2018
    Summary VisionQuest Biomedical LLC (VisionQuest) is a medical device company that develops medical imaging tools for the diagnostic services. The company’s products include eyestar, DR-RACS, and neurotherm. Its eyestar product is a total eye disease screening program package, DR-RACS is an automated …
  • Civitas Solutions, Inc.:企業の戦略・SWOT・財務情報
    Civitas Solutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary Civitas Solutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Inhibrx LP:製薬・医療:M&Aディール及び事業提携情報
    Summary Inhibrx LP (Inhibrx) is a biotherapeutic company that develops drugs for treatment of oncology, infectious disease and inflammatory diseases. The company’s products include therapeutic proteins with multivalent and multi specific molecules which are designed from their antibody technology. I …
  • Canara Bank (CANBK):企業の財務・戦略的SWOT分析
    Canara Bank (CANBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Sandvik AB (SAND):企業の財務・戦略的SWOT分析
    Sandvik AB (SAND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • United Insurance Holdings Corp.:企業の戦略・SWOT・財務情報
    United Insurance Holdings Corp. - Strategy, SWOT and Corporate Finance Report Summary United Insurance Holdings Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Japan Oil, Gas and Metals National Corp:企業の戦略的SWOT分析
    Japan Oil, Gas and Metals National Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • IXICO Plc (IXI)-製薬・医療分野:企業M&A・提携分析
    Summary IXICO Plc (IXICO), formerly Phytopharm plc is a provider of clinical trial services and technology for the evaluation of imaging endpoints. The company provides clinical trial services for assessing the safety and efficacy of drugs. Its product portfolio includes web-based platform to transf …
  • Intellia Therapeutics Inc (NTLA):企業の財務・戦略的SWOT分析
    Summary Intellia Therapeutics Inc (Intellia Therapeutics) is a genome editing company. It develops proprietary curative therapeutics using CRISPR/Cas9 technology. The company develops in vivo programs for the treatment of liver diseases such as alpha-1 antitrypsin deficiency, and primary hyperoxalur …
  • Kohler Co:企業の戦略的SWOT分析
    Kohler Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Rexnord Corp (RXN):電力:M&Aディール及び事業提携情報
    Summary Rexnord Corp (Rexnord) offers process and motion control, and water management products. The company designs, manufactures, markets and services mechanical components, and water flow control and conservation products. Its product portfolio includes motion control products, aerospace componen …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆